Prenatal and New-born Genetic Testing Market Analysis

Prenatal and New-born Genetic Testing Market Analysis

The Down’s syndrome segment accounted for around 41% of the market share in 2020 and is estimated to attain a CAGR of 11.4% by 2027 owing to growing number of infants suffering from Down’s syndrome. The Down’s syndrome represents one of the most prevalent chromosomal anomalies related to multiple congenital defects and leads to mental retardation & even severe health-related complication and defects. According to the World Health Organization, Down’s syndrome condition is observed in 1 out of 1,000 to 1,100 live births, globally. Similarly, in India, the condition is reported in every 1 child per 850- 900 live births. In addition, as per the Centers for Diseases Control and Prevention (CDC), the prevalence of this condition over the recent years has increased by around 30%. The rising prevalence of Down’s syndrome and number of paediatrics suffering from the condition will increase the use of prenatal and new-born genetic testing, thereby facilitating the industry revenue.

To get key market trends

  Download Free Sample

The prenatal and new-born genetic testing market for hospital segment exceeded USD 2.1 billion in 2020 driven by the accessibility to modern technology in new-born and prenatal genetic testing and the favourable reimbursement policies. The demand for these healthcare facilities is increasing attributed to the high utilization rate of prenatal and new-born genetic testing in hospitals. Rising investment by government organizations in hospitals along with an increasing number of experienced and trained professionals is further promoting the industry demand. Additionally, preference for prenatal and new-born genetic testing at hospitals is increasing owing to high number of births in hospitals along with availability of infant genetic testing. The hospitals can offer genetic testing services in the shortest time.

U.S. dominated the North America prenatal and new-born genetic testing market in 2020 and is poised to register growth of over 10.3% during 2021 to 2027. The dominant revenue share is pertaining to host of factors including high incidence of genetic disorders and growing demand for minimally invasive genetic testing across the country. According to the Centers for Disease Control and Prevention (CDC), around 6,000 babies in the U.S. are born with Down’s syndrome and this condition affects at least 1 out of every 700 babies. Rising cases of pregnancy in late years, i.e. after 35 years increases the risk of giving birth to an infant with chromosomal anomaly. Over 80 percent of the children suffering from trisomy 21 or Down’s syndrome condition are given birth by mothers aged over 35 years. These adverse events along with rise in other genetic factors are anticipated to drive the acceptance of prenatal and new-born genetic testing in the country.

Germany prenatal and new-born genetic testing market is slated to expand at a CAGR of 11.8% and will cross USD 508 million by 2027 impelled by the rising preterm birth rate, high maternal mortality, and growing prevalence of chromosomal anomalies. According to a published report, the number of infants born preterm was 66,730 in 2017, in Germany. This constitutes to 8.6% of the total children born in the year. Furthermore, over 80,000 people were suffering from cystic fibrosis in Germany, with the condition affecting every 1 individual out of 3,300. High incidence of genetic disorders, and congenital abnormalities are projected to fuel the demand for prenatal and new-born genetic testing, thereby fostering the industry progression in Germany during the forecast timeline.